Acumen Pharmaceuticals Inc ABOS presented topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage amyloid beta oligomers (AβO) targeting antibody therapy in early AD, at the Alzheimer's Association International Conference (AAIC) 2023.
Topline results demonstrated that ACU193 was generally well-tolerated, meeting the primary objective of the Phase 1 study in both single and multiple doses in 60 participants with early AD.
Dose levels were 2, 10, 25, and 60 mg/kg for one to three doses administered intravenously.
Higher doses of ACU193 (60 mg/kg every 4 weeks [Q4W] and 25 mg/kg every 2 weeks [Q2W]) showed a statistically significant reduction in amyloid plaque load.
25% reduction in 60 mg/kg Q4W cohort at day 63 and a 20% reduction in 25 mg/kg Q2W cohort at day 70.
The overall rate of amyloid-related imaging abnormalities – edema (brain swelling) (ARIA-E) was 10.4%, including one symptomatic ARIA-E (2.1%).
Another 8.3% developed bleeding in the brain associated with treatment, known as ARIA-H.
Pharmacokinetic results in serum and cerebrospinal fluid (CSF) demonstrated statistically significant dose proportionality and support monthly dosing of ACU193.
Statistically significant, dose-related central target engagement was observed.
Acumen plans to discuss these results with regulators to assess the next steps for the clinical development of ACU193 and determine a timeline for progressing to a Phase 2/3 clinical study.
Price Action: ABOS shares are up 97.40% at $12.39 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.